Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

AstraZeneca and IIDF sign a memorandum of collaboration

AstraZeneca, an international biopharmaceutical company, and the Internet Initiatives Development Fund (IIDF) signed a Memorandum of Intent to collaborate in the area of digital solutions for the pharmaceutical industry

GlobalData expects that Merck will set to lead licensing deals in 2018

Companies’ financial success is often down to the strategic deals they are able to make with other pharmaceutical companies to enable them to develop the next leading drug in the market, observes GlobalData

Array Biopharma takes legal steps against AstraZeneca

pills and money
Array Biopharma Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs, is suing AstraZeneca over royalties for a cancer drug

Syndax entered a clinicial trial collaboration with AstraZeneca

drug development
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced a new clinical collaboration with AstraZeneca

Innate Pharma and MedImmune started a new clinical trial collaboration

cancer lab diagnostic
Innate Pharma announced that it has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca

The University of Geneva and AstraZeneca manage a new research project

microbiology plates
The research project DRIVE-AB has determined that a market entry reward of $1 billion per antibiotic globally could significantly increase the number of new antibiotics coming to the market in the next 30 years

Cambrex and AstraZeneca entered a long-term manufacturing agreement

Cambrex Corporation held an opening ceremony with AstraZeneca at its Karlskoga, Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies

AstraZeneca obtained EU approval for its asthma drug

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the European Commission has approved Fasenra

AstraZeneca and Imperial College London set up a new research collaboration

AstraZeneca and Imperial College London announced a new research collaboration in respiratory diseases

AstraZeneca conducts 45 clinical trials of its medicinal products in Russia

The General Director of AstraZeneca Russia & Eurasia said that the company is one of the global market leaders in terms of the relative investments in R&D

AstraZeneca will localize 10 drugs under SPIC arrangements

astrazeneca plant
In the next three years AstraZeneca intends to use the Special Investment Contract arrangements for localizing the manufacturing of 10 medicinal products

AstraZeneca signs an agreement with Tatarstan to develop R&D projects

Tatarstan Investment Development Agency and AstraZeneca signed a cooperation agreement for the development of R&D projects in the pharmaceutical industry.

AstraZeneca and leading Russian university join together their research efforts

AstraZeneca and the National Research Nuclear University MEPhI (Moscow Engineering Physics Institute) have signed a Memorandum of Intent on collaboration

AstraZeneca and Chinese fund established a drug development company

AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund to form a stand-alone company

Russia registers Tagrisso – an innovative cancer drug

AstraZeneca announced that it received the registration certificate in Russia for Tagrisso® (osimertinib)

Roivant Sciences starts cooperation with AstraZeneca

test tubes
Roivant Sciences announced that it has entered into a development partnership with AstraZeneca for a deprioritized investigational drug